Immune science

Immune cell analysis reveals the amount of SARS-CoV-2 in blood is a strong predictor of mortality

CITF-funded researchers Drs. Daniel Kaufmann, Andrés Finzi and Nicolas Chomont from the Université de Montréal and the Université de Montréal hospital research centre (CRCHUM), along with their collaborators, found that the amount of viral mRNA  in the blood can help identify hospitalized patients who will suffer severe COVID-19, and even death.

2022-04-18T10:17:10-04:00December 13, 2021|Immune science|

Older adults likely remain at higher risk for COVID-19 − particularly infections caused by variants of concern − even after vaccination

In a recent CITF-funded pre-print, therefore not yet peer-reviewed, Drs. Mark Brockman and Zabrina Brumme from Simon Fraser University and Dr. Marc Romney from the University of British Columbia studied immune responses following COVID-19 vaccination in over 150 adults aged 24-98 years.

2022-04-18T10:17:29-04:00September 14, 2021|Immune science|

Poorer neighbourhoods and racialized communities continue to lag behind in vaccine coverage: latest Canadian Blood Services results

The gap between the rates of COVID-19 infection and vaccination among racialized and non-racialized Canadians continues to exist, as does the gap between Canadians from lower- and higher-income neighbourhoods. The CITF-funded Canadian Blood Services Serosurveillance Study has released its latest report for the month of May 2021. While the latest data show that the [...]

2021-08-10T16:01:33-04:00August 10, 2021|Immune science|

Early results from a national study confirm antibody levels are stronger after receiving two doses

Initial preliminary results from the Canadian Partnership for Tomorrow’s Health (CanPath) COVID-19 Antibody Study, based on close to 6,000 dried blood spot samples collected between February 8 and May 17, 2021, show a high degree of variability in the level of antibodies produced by a single dose of a COVID-19 vaccine. These findings highlight the importance of accelerating second doses as the Delta variant continues to spread, particularly with the vast majority of Canadians having received only a single vaccine dose.

2021-06-23T09:12:41-04:00June 23, 2021|Immune science, Media Releases|
Go to Top